MAPK8 and metastatic neoplasm: Various experimental models have demonstrated that direct JNK inhibition is able to block primary tumor growth, impede the tumor-initiating potential of cancer stem cells, modulate the structural and cellular landscape of the metastatic niche, and thereby inhibit metastatic disease progression.